Clinical Trial

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Study acronym: TROPION-Lung17
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).
Protocol Amendment History 1 change
notable Trial sites expanded: 198 -> 204 locations 2026-04-30
Trial Details
NCT Number NCT07291037
Lead Sponsor AstraZeneca
Collaborators: Daiichi Sankyo
Conditions Non-small Cell Lung Cancer (NSCLC)
Enrollment 400 participants
Start Date 2025-10-31
Primary Completion 2029-01-29 (estimated)
Study Completion 2029-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-01